<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02117297</url>
  </required_header>
  <id_info>
    <org_study_id>NYMC-504</org_study_id>
    <secondary_id>L 10,394</secondary_id>
    <nct_id>NCT02117297</nct_id>
  </id_info>
  <brief_title>SCT Plus Immune Therapy in Average Risk AML/MDS</brief_title>
  <official_title>Allogeneic Stem Cell Transplantation Following by Targeted Immune Therapy) (Gemtuzumab Ozogamicin) in Average Risk Acute Myelogenous Leukemia and Myelodysplastic Syndrome (AML/MDS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York Medical College</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>New York Medical College</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Allogeneic stem cell transplantation followed by targeted immune therapy with Gemtuzumab&#xD;
      Ozogamicin (Mylotarg) will be given to patients with average risk AML or MDS.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Reduced intensity conditioning regimen of Busulfan (Bu) and Fludarabine (Flu) +&#xD;
      Anti-Thymocyte Globulin (ATG ) (unrelated donors only) or reduced toxicity conditioning&#xD;
      regimen of Bu/Flu/alemtuzumab, or reduced hepatic toxicity regimen of melphan/Flu/alemtuzumab&#xD;
      and AlloSCT, followed by Gemtuzumab Ozogamicin consolidation in patients with average risk&#xD;
      AML/MDS meeting eligibility criteria.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>to evaluate incidence of graft failure</measure>
    <time_frame>Day +42</time_frame>
    <description>If three or more of the first ten patients experience primary or secondary graft failure, we will discontinue the study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>to evaluate survival rates</measure>
    <time_frame>1 year</time_frame>
    <description>Event-free survival and overall survival after RI AlloSCT and targeted immunotherapy in patients with average risk AML/MDS.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>to determine toxicity</measure>
    <time_frame>1 year</time_frame>
    <description>to monitor for serious adverse events related to protocol investigational therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Minor histocompatibility antigen</measure>
    <time_frame>1 year</time_frame>
    <description>To measure the minor histocompatibility antigen expression on AML tissue, donor and recipient, and the development of MHA specific CTLs post AlloSCT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chimerism</measure>
    <time_frame>1 year</time_frame>
    <description>To determine the degree of mixed/complete donor chimerism after RI AlloSCT in patients with average risk AML/MDS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Graft-versus-host disease</measure>
    <time_frame>1 Year</time_frame>
    <description>To estimate the risk of acute and chronic GVHD following RI AlloSCT and FK506/MMF GVHD prophylaxis in patients with average risk AML/MDS.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">26</enrollment>
  <condition>Acute Myelogenous Leukemia</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <arm_group>
    <arm_group_label>Gemtuzumab Ozogamicin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Consolidation therapy with GO will be administered between days 60 and 180 post transplantation when the ANC is &gt;1000/mm3 and platelet count is &gt;40,000/mm3 untransfused x 3 days after AlloSCT and again at minimum 8 weeks later.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemtuzumab Ozogamicin</intervention_name>
    <description>Gemtuzumab, 9.0 mg/m2, will be given IV over 2 hours two times post allogeneic transplantation.</description>
    <arm_group_label>Gemtuzumab Ozogamicin</arm_group_label>
    <other_name>Mylotarg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Disease Status:&#xD;
&#xD;
          -  AML 1st CR with a matched family donor&#xD;
&#xD;
          -  AML 1st CR with unrelated donor&#xD;
&#xD;
          -  AML 2nd CR or CRP&#xD;
&#xD;
          -  MDS and &lt; or = 5% bone marrow myeloblasts at diagnosis&#xD;
&#xD;
        Disease Immunophenotype:&#xD;
&#xD;
          -  Disease must express a minimum of &gt; or = 10% CD33 positivity for patients with AML&#xD;
&#xD;
        Organ Function:&#xD;
&#xD;
          -  Adequate renal function, adequate liver function, adequate cardiac function, adequate&#xD;
             pulmonary function&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with active CNS AML disease at time of preparative regimen&#xD;
&#xD;
          -  Secondary MDS&#xD;
&#xD;
          -  Poor cytogenetics&#xD;
&#xD;
          -  Female patients who are pregnant&#xD;
&#xD;
          -  Karnofsky &lt;70% or Lansky &lt;50% if 10 years or less&#xD;
&#xD;
          -  Age &gt;25 years&#xD;
&#xD;
          -  Seropositive for HIV&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mitchell S. Cairo, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York Medical College</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New York Medical College</name>
      <address>
        <city>Valhalla</city>
        <state>New York</state>
        <zip>10595</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>April 8, 2014</study_first_submitted>
  <study_first_submitted_qc>April 15, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 17, 2014</study_first_posted>
  <last_update_submitted>November 11, 2021</last_update_submitted>
  <last_update_submitted_qc>November 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>New York Medical College</investigator_affiliation>
    <investigator_full_name>Mitchell Cairo</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemtuzumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

